ALTO NEUROSCIENCE INC (ANRO) competitors & alternatives
Health Care · NYSE
ALTO NEUROSCIENCE INC (ANRO)'s top competitors and alternatives — its most similar public companies — include Guardant Health, Inc. (GH), NEUMORA THERAPEUTICS INC (NMRA), RAPPORT THERAPEUTICS INC (RAPP), ATAIBECKLEY INC (ATAI), ANAVEX LIFE SCIENCES CORP (AVXL), BRIGHT MINDS BIOSCIENCES INC (DRUG), IDEAYA BIOSCIENCES INC (IDYA), XENON PHARMACEUTICALS INC (XENE), NRX Pharmaceuticals, Inc. (NRXP), OVID THERAPEUTICS INC (OVID), REZOLUTE INC (RZLT) and TANGO THERAPEUTICS INC (TNGX). These are ALTO NEUROSCIENCE INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ANRO competitors & alternatives
-
Guardant Health, Inc.GHHealth Care
Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early…
$150.75 (as of 2026-07-22) · market cap $19.8B
-
NEUMORA THERAPEUTICS INCNMRAHealth Care
Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
$1.54 (as of 2026-07-22) · market cap $298M
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
BRIGHT MINDS BIOSCIENCES INCDRUGHealth Care
Bright Minds Biosciences is a clinical-stage biotechnology company developing next-generation serotonin-targeting therapies for neuropsychiatric, epilepsy, and…
$75.46 (as of 2026-07-22) · market cap $762M
-
IDEAYA BIOSCIENCES INCIDYAHealth Care
IDEAYA is a precision oncology company leveraging tumor genetics and DNA damage response pathways to develop targeted cancer therapies, with multiple…
$35.00 (as of 2026-07-22) · market cap $3.3B
-
XENON PHARMACEUTICALS INCXENEHealth Care
A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and…
$66.18 (as of 2026-07-22) · market cap $6.7B
-
NRX Pharmaceuticals, Inc.NRXPHealth Care
Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three…
$4.48 (as of 2026-07-22) · market cap $186M
-
OVID THERAPEUTICS INCOVIDHealth Care
A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental…
$2.38 (as of 2026-07-22) · market cap $438M
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
TANGO THERAPEUTICS INCTNGXHealth Care
A precision oncology company utilizing a proprietary functional genomics platform to discover and develop targeted, synthetic-lethal cancer therapies.
$28.10 (as of 2026-07-22) · market cap $4.6B
Not quite? Describe exactly what you want →
Peers are ALTO NEUROSCIENCE INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ALTO NEUROSCIENCE INC (ANRO).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.